Logo

HU CFAR Grand Rounds : Optimizing PrEP Adherence: What do we know, and what do we need to know? - Shared screen with speaker view
Kenneth Mayer
18:38
Please add your questions to the chat
Monty Montano
25:01
Do pharmacogenetic differences influence interpreting average drug level adherence, from urine and hair?
Gerld Sharp
35:14
are there plans to extend the urine test for tenofovir to other ARVs?
Yannis Mameletzis
42:00
this is a fantastic seminar; I joined late, will recording be sent to participants?
Kenneth Mayer
42:09
Monica: wonderful talk. will be good for each speaker to address how their approaches might be used in the real world vs. in research studies
HU CFAR
43:55
Hi, we will post the recording to our website https://cfar.globalhealth.harvard.edu/
Yannis Mameletzis
46:57
Greetings from Athens, there is a great app by UK group which is focused on both daily dosing and 211. https://mobile.twitter.com/preptrackapp/status/1457398700431532037
Udodirim Onwubiko
47:00
Thank you for a wonderful presentation! What happens when the pill is ingested but the study participant is not wearing the reader? Does this count as a misses dose?
Yannis Mameletzis
47:01
Nice to see you Ken!
Kenneth Mayer
47:36
Hi Yannis. glad you could attend
Natasha Ludwig-Barron
53:36
Dr Gandhi- I know there was pushback on taking hair samples from the African Americans from community members, particularly African American women. How have you addressed this in the US? And is this an issue in Africa?
Cara Frigand
54:49
PrEP for cisgender women seems to be considered a low priority, at least in the US. What are your feelings on new PrEP drugs like Descovy, which did not even bother to include biological females in their clinical trials? And is Truvada as effective for ciswomen as for men/trans women (perhaps drawing from data from sub-Saharan Africa)? Any gender differences in adherence in heterosexual couples?
Yannis Mameletzis
01:01:02
Thanks great talk Christina!
Yannis Mameletzis
01:02:01
Question: how do you account for 211/ED PrEP use - or will you - in future work? I know in the US the dosing recommended is daily - and there are challenges related to 211 dosing, but I am of the mindset giving people options. FYI, WHO will move towards a 211 dosing recommendation for all cis-gender men in coming months.
Yannis Mameletzis
01:02:51
(I know of course in SF and Boston your clinicians have been also providing guidance to PrEP users on 211)
Liz Salomon
01:05:56
Hi, Ken and Conall, So nice to be in your presence and to see our work on Life-Steps being adapted for PrEP purposes in such amazing ways (who would have thought we'd have this great resource available when we first wrote about this back in 2000?). Miss you all and hope that all is well with both of you. Many thanks to all the great presenters today!
Kenneth Mayer
01:12:09
Many thanks to each of you for wonderful presentations
Brian Minalga
01:12:28
Great event. Thanks!
Paloma Blair
01:12:36
Thank you all
Yannis Mameletzis
01:12:37
This was really wonderful, thank you for inviting people from Yale and not from Harvard!
Natasha Ludwig-Barron
01:12:37
Thank you all!! Great presentations
Sari Reisner
01:12:38
Thank you!